{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:29:26Z","timestamp":1789000166998,"version":"build-2803163510"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Nipah virus (NiV) poses a significant threat to human and livestock populations across South and Southeast Asia. Vaccines are required to reduce the risk and impact of spillover infection events. Pigs can act as an intermediate amplifying host for NiV and, separately, provide a preclinical model for evaluating human vaccine candidate immunogenicity. The aim of this study was therefore to evaluate the immunogenicity of an mRNA vectored NiV vaccine candidate in pigs. Pigs were immunized twice with 100 \u03bcg nucleoside-modified mRNA vaccine encoding soluble G glycoprotein from the Malaysia strain of NiV, formulated in lipid nanoparticles. Potent antigen-binding and virus neutralizing antibodies were detected in serum following the booster immunization. Antibody responses effectively neutralized both the Malaysia and Bangladesh strains of NiV but showed limited neutralization of the related (about 80% amino acid sequence identity for G) Hendra virus. Antibodies were also capable of neutralizing NiV glycoprotein mediated cell-cell fusion. NiV G-specific T cell cytokine responses were also measurable following the booster immunization with evidence for induction of both CD4 and CD8 T cell responses. These data support the further evaluation of mRNA vectored NiV G as a vaccine for both pigs and humans.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1384417","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T04:24:06Z","timestamp":1714019046000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Evaluation of the immunogenicity of an mRNA vectored Nipah virus vaccine candidate in pigs"],"prefix":"10.3389","volume":"15","author":[{"given":"Miriam","family":"Pedrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca K.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lobna","family":"Medfai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazia","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalan","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Donofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Pardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/82_2020_202","article-title":"Messenger RNA-based vaccines against infectious diseases","volume":"440","author":"Alameh","year":"2022","journal-title":"Curr Top Microbiol Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-med-042420-112725","article-title":"mRNA vaccines in the COVID-19 pandemic and beyond","volume":"73","author":"Hogan","year":"2022","journal-title":"Annu Rev Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1038\/s41467-022-32149-8","article-title":"Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses","volume":"13","author":"Pardi","year":"2022","journal-title":"Nat Commun"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004746","article-title":"An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs","volume":"10","author":"Schnee","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.13345\/j.cjb.220853","article-title":"[Preparation and immunogenicity evaluation of mRNA vaccine against porcine epidemic diarrhea]","volume":"39","author":"Yang","year":"2023","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2019.00016","article-title":"Vaccine development for Nipah virus infection in pigs","volume":"6","author":"McLean","year":"2019","journal-title":"Front Vet Sci"},{"key":"B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-3283-3_1","article-title":"Overview of experimental vaccines and antiviral therapeutics for Henipavirus infection","volume-title":"Nipah Virus: Methods and Protocols","author":"Satterfield","year":"2023"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S493","DOI":"10.1093\/infdis\/jiz553","article-title":"Evaluation of a single-dose nucleoside-modified messenger RNA vaccine encoding Hendra virus-soluble glycoprotein against lethal Nipah virus challenge in Syrian hamsters","volume":"221","author":"Lo","year":"2020","journal-title":"J Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772864","article-title":"Chimeric fusion (F) and attachment (G) glycoprotein antigen delivery by mRNA as a candidate Nipah vaccine","volume":"12","author":"Loomis","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8010115","article-title":"Bovine Herpesvirus-4-vectored delivery of Nipah virus glycoproteins enhances T cell immunogenicity in pigs","volume":"8","author":"Pedrera","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41541-023-00786-9","article-title":"A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax","volume":"8","author":"Kunkeaw","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA","volume":"15","author":"Baiersd\u00f6rfer","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0166-0934(01)00377-9","article-title":"A rapid immune plaque assay for the detection of Hendra and Nipah viruses and anti-virus antibodies","volume":"99","author":"Crameri","year":"2002","journal-title":"J Virological Methods"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001506","article-title":"Micro-fusion inhibition tests: quantifying antibody neutralization of virus-mediated cell\u2013cell fusion","volume":"102","author":"Thakur","year":"2021","journal-title":"J Gen Virol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.288.5470.1432","article-title":"Nipah virus: A recently emergent deadly paramyxovirus","volume":"288","author":"Chua","year":"2000","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijid.2018.05.015","article-title":"Enhancing preparation for large Nipah outbreaks beyond Bangladesh: Preventing a tragedy like Ebola in West Africa","volume":"72","author":"Donaldson","year":"2018","journal-title":"Int J Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1038\/s41467-018-05482-0","article-title":"Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies","volume":"9","author":"Pardi","year":"2018","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2206333119","article-title":"Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses","volume":"119","author":"McMahon","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00263-06","article-title":"Recombinant nipah virus vaccines protect pigs against challenge","volume":"80","author":"Weingartl","year":"2006","journal-title":"J Virol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.08.028","article-title":"Protection against henipaviruses in swine requires both, cell-mediated and humoral immune response","volume":"34","author":"Pickering","year":"2016","journal-title":"Vaccine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1384417\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T04:24:12Z","timestamp":1714019052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1384417\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2024.1384417"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1384417","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"article-number":"1384417"}}